Clinical Trials | April 05, 2024
Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Subscribe To Our Newsletter & Stay Updated
